Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 15/20 | 0.75 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14514817 | 1.00 | KCNH2 (0.75) | KCNH2SLC2A1MCHR1PDE5A | |
| SCHEMBL13286290 | 1.00 | KCNH2 (0.75) | KCNH2SLC2A1MCHR1PDE5A | |
| SCHEMBL10226462 | 1.00 | KCNH2 (0.75) | KCNH2SLC2A1MCHR1PDE5A | |
| SCHEMBL3126601 | 0.87 | KCNH2 (0.67) | KCNH2SLC2A1MCHR1PDE5A | |
| SCHEMBL5263322 | 0.84 | KCNH2 (0.71) | KCNH2SLC2A1MCHR1PDE5A | |
| SCHEMBL5263317 | 0.84 | KCNH2 (0.71) | KCNH2SLC2A1MCHR1PDE5A | |
| SCHEMBL14341171 | 0.84 | KCNH2 (0.77) | KCNH2SLC2A1MCHR1 | |
| SCHEMBL5261655 | 0.84 | KCNH2 (0.77) | KCNH2SLC2A1MCHR1 | |
| SCHEMBL5261660 | 0.84 | KCNH2 (0.77) | KCNH2SLC2A1MCHR1 | |
| SCHEMBL3683660 | 0.83 | KCNH2 (0.58) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239260-A1 | Novel compounds with antibacterial activity | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-7223776-B2 | Compounds with anti-bacterial activity | MORPHOCHEM AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MORPHOCHEM AG | 2006-02-23 | — | — | US | disclosed |
| EP-1551829-A2 | NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035569-A2 | NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040949-A1 | Novel compounds with antibacterial activity | MRPL21, Q6ZSR9, MRPL19 | KCNH2 2411/4885SLC2A1 4070/4885MCHR1 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.